A Phase 3 interventional study of Regorafenib (Stivarga, BAY73-4506) and Placebo in Carcinoma, Hepatocellular, sponsored by Bayer. Completed at 147 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-20.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing regorafenib in Carcinoma, Hepatocellular — 7 open to participants now, 9 under way, none of them phase 3. regorafenib · Carcinoma, Hepatocellular.
Among the 22 studies testing regorafenib in Carcinoma, Hepatocellular, this one is the 2nd largest by enrollment, is the only one that started in 2013, is one of 2 in phase 3, and was the 2nd registered.
3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.
Browse Carcinoma, Hepatocellular studies →7 of the 22 studies testing regorafenib in Carcinoma, Hepatocellular are open now, in 4 countries. Recruiting first, the newest first:
Peking Union Medical College Hospital · Sites in China
Ages 18+
Humanity & Health Medical Group Limited · Sites in Hong Kong
Ages 18+
Institut Bergonié · Sites in France
Ages 18+
Asan Medical Center · Sites in Korea, Republic of
Ages 19+
Ju Hyun Shim · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
regorafenib: first FDA approval 2012 (STIVARGA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 19 · Phase 3 2
First in 2009; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 573 is above the median of 54 across 2,620 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 33 across the 22 interventional studies. Of the 11 that completed or were terminated, 4 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 22 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
34 studies in Carcinoma, Hepatocellular by Bayer: 1 open now, 2 under way, none of them phase 3. Of 31 finished, 12 (39%) have results posted.
Among the 34 studies in Carcinoma, Hepatocellular by Bayer, this one is the 4th largest by enrollment of the 20 interventional ones that give a count, is one of 7 that started in 2013, is one of 6 in phase 3, and was the 22nd registered.
Bayer’s Carcinoma, Hepatocellular studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing regorafenib in Carcinoma, Hepatocellular, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bayer’s 34 in Carcinoma, Hepatocellular:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study was to evaluate efficacy and safety of regorafenib in patients with advanced liver cancer who had progressed after sorafenib treatment. Patients were treated with regorafenib or placebo using a 2:1 randomization scheme.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Local or loco-regional therapy of intrahepatic tumor lesions (e.g. surgery, radiation therapy, hepatic arterial embolization, chemoembolization, radiofrequency ablation, percutaneous ethanol injection, or cryoablation) must have been completed >/=4 weeks before first dose of study medication. Note: patients who received sole intrahepatic intraarterial chemotherapy, without lipiodol or embolizing agents are not eligible.
Exclusion Criteria :
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
160 mg orally (p.o.) every day (qd) for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off) plus BSC (Best Supportive Care)
Drug: Regorafenib (Stivarga, BAY73-4506)
4 matching placebo tablets for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off) plus BSC
Drug: Placebo
Regorafenib, 40 mg tablets
Placebo tablets matching in appearance
Overall Survival (OS)
Overall Survival (OS) was defined as the time from date of randomization (Day 1) to death due to any cause. Subjects still alive at the time of analysis were censored at their last date of last contact.
Time frame: From randomization (Day 1) of the first subject until 419 days later
Time to Progression (TTP)
TTP was the time (days) from randomization to radiological or clinical disease progression assessed by independent radiological review. Median and 95% confidence interval were reported for the modified response evaluation criteria in solid tumors (mRECIST) and response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) analysis sets. Subjects still alive at the time of analysis were censored at their last date of last contact.
Time frame: From date of randomization until 30 days after last study treatment (assessed every 6 weeks until PD; and after 8 cycle assessed every 12 weeks) (approximately 33 months)
Progression Free Survival (PFS)
Progression Free Survival (PFS) was defined as the time (days) from date of randomization to date of disease progression (radiological or clinical) or death due to any cause, if death occurs before progression was documented. Death in the absence of progression was a PFS event only if it occurred within the 12+1 weeks for subjects who discontinued treatment prior to cycle 8 and 24+2 weeks for subjects who discontinued treatment after to cycle 8 of the last evaluable tumor assessment; PFS were censored at the date of the last evaluable tumor assessment, if it occurred later. Median and 95% confidence interval 95% were reported for the mRECIST and RECIST 1.1 analysis sets. Subjects still alive at the time of analysis were censored at their last date of last contact.
Time frame: From date of randomization until 30 days after last study treatment (assessed every 6 weeks until PD; and after 8 cycle assessed every 12 weeks)
Objective Tumor Response Rate (ORR)
Objective tumor response rate (ORR) was defined as the percentage of subjects whose best tumor response CR or Partial Response (PR) observed during trial period assessed according to the mRECIST criteria and RECIST 1.1. CR= Disappearance of all clinical and radiological evidence of tumor (both target and non-target). Any pathological lymph nodes (whether target or non-target) must have a reduction in short axis to \< 10 mm. PR= At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum, no unequivocal progression of existing non target lesions and no appearance of new lesions. Subjects prematurely discontinuing without an assessment were to be considered non-responders for the analysis.
Time frame: From date of randomization until 30 days after last study treatment (assessed every 6 weeks until PD; and after 8 cycle assessed every 12 weeks) (approximately 33 months)
Disease Control Rate (DCR)
Disease control rate (DCR) was defined as the percentage of subjects whose best response was CR (CR: disappearance of all clinical and radiological evidence of tumor (both target and non-target).), PR (PR: at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum, no unequivocal progression of existing non-target lesions, and no appearance of new lesions.), or stable disease (SD) (SD: steady state of disease. Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, no unequivocal progression of existing non-target lesions, and no appearance of new lesions.) according to RECIST and RECIST 1.1 criteria. SD had to be maintained for at least 6 weeks from the first demonstration of that rating.
Time frame: From date of randomization until 30 days after last study treatment (assessed every 6 weeks until PD; and after 8 cycle assessed every 12 weeks) (approximately 33 months)
Overall Survival (OS)
Overall Survival (OS) was defined as the time from date of randomization (Day 1) to death due to any cause
Time frame: From randomization (Day 1) of the first subject to end of follow upto 1710 days
The study was conducted between 14 May 2013 (first subject first visit), 29 February 2016 (primary completion date) and 05-July-2019 (Last Patient Last Visit =End of study).
| Milestone | Placebo | Regorafenib 160 mg (BAY73-4506) |
|---|---|---|
| Started | 194 | 379 |
| Treated | 193 | 374 |
| Entered survival fu | 145 | 291 |
| Completed | 132 | 258 |
| Not completed | 62 | 121 |
| Withdrew: Withdrawal by subject | 3 | 10 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Lost to follow-up | 4 | 10 |
| Withdrew: End of survival follow-up not available | 2 | 2 |
| Withdrew: Data collection finished | 4 | 14 |
| Withdrew: Other | 0 | 1 |
| Withdrew: Did not enter survival follow up | 49 | 83 |
Overall Survival (OS) was defined as the time from date of randomization (Day 1) to death due to any cause. Subjects still alive at the time of analysis were censored at their last date of last contact.
| days | Placebo | Regorafenib 160 mg (BAY73-4506) |
|---|---|---|
| Overall Survival (OS) | 237 ± 192 | 323 ± 276 |
TTP was the time (days) from randomization to radiological or clinical disease progression assessed by independent radiological review. Median and 95% confidence interval were reported for the modified response evaluation criteria in solid tumors (mRECIST) and response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) analysis sets. Subjects still alive at the time of analysis were censored at their last date of last contact.
| days | Placebo | Regorafenib 160 mg (BAY73-4506) |
|---|---|---|
| mRECIST | 45 ± 44 | 97 ± 87 |
| RECIST 1.1 | 45 ± 44 | 119 ± 87 |
Progression Free Survival (PFS) was defined as the time (days) from date of randomization to date of disease progression (radiological or clinical) or death due to any cause, if death occurs before progression was documented. Death in the absence of progression was a PFS event only if it occurred within the 12+1 weeks for subjects who discontinued treatment prior to cycle 8 and 24+2 weeks for subjects who discontinued treatment after to cycle 8 of the last evaluable tumor assessment; PFS were censored at the date of the last evaluable tumor assessment, if it occurred later. Median and 95% confidence interval 95% were reported for the mRECIST and RECIST 1.1 analysis sets. Subjects still alive at the time of analysis were censored at their last date of last contact.
| days | Placebo | Regorafenib 160 mg (BAY73-4506) |
|---|---|---|
| mRECIST | 45 ± 44 | 95 ± 86 |
| RECIST 1.1 | 45 ± 44 | 102 ± 87 |
Objective tumor response rate (ORR) was defined as the percentage of subjects whose best tumor response CR or Partial Response (PR) observed during trial period assessed according to the mRECIST criteria and RECIST 1.1. CR= Disappearance of all clinical and radiological evidence of tumor (both target and non-target). Any pathological lymph nodes (whether target or non-target) must have a reduction in short axis to \< 10 mm. PR= At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum, no unequivocal progression of existing non target lesions and no appearance of new lesions. Subjects prematurely discontinuing without an assessment were to be considered non-responders for the analysis.
| percentage of subjects | Placebo | Regorafenib 160 mg (BAY73-4506) |
|---|---|---|
| mRECIST | 4.1 | 10.8 |
| RECIST 1.1 | 2.6 | 6.6 |
Disease control rate (DCR) was defined as the percentage of subjects whose best response was CR (CR: disappearance of all clinical and radiological evidence of tumor (both target and non-target).), PR (PR: at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum, no unequivocal progression of existing non-target lesions, and no appearance of new lesions.), or stable disease (SD) (SD: steady state of disease. Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, no unequivocal progression of existing non-target lesions, and no appearance of new lesions.) according to RECIST and RECIST 1.1 criteria. SD had to be maintained for at least 6 weeks from the first demonstration of that rating.
| percentage of subjects | Placebo | Regorafenib 160 mg (BAY73-4506) |
|---|---|---|
| mRECIST | 36.1 | 65.2 |
| RECIST 1.1 | 34.5 | 65.7 |
Overall Survival (OS) was defined as the time from date of randomization (Day 1) to death due to any cause
| days | Placebo | Regorafenib 160 mg (BAY73-4506) |
|---|---|---|
| Overall Survival (OS) | 241 ± 196 | 326 ± 278 |
Collected over Adverse event data were collected after start of study drug administration until 30 days after end of study treatment over a period of approximately three years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 176/193 (91.2%) | 92/193 (47.7%) | 162/193 (83.9%) |
| Regorafenib (Stivarga, BAY73-4506) | 324/374 (86.6%) | 194/374 (51.9%) | 366/374 (97.9%) |
| Event | Placebo | Regorafenib (Stivarga, BAY73-4506) |
|---|---|---|
| General physical health deteriorationGeneral disorders | 25/193 | 47/374 |
| Hepatic failureHepatobiliary disorders | 9/193 | 9/374 |
| AscitesGastrointestinal disorders | 6/193 | 10/374 |
| Hepatic encephalopathyNervous system disorders | 3/193 | 9/374 |
| PneumoniaInfections and infestations | 1/193 | 8/374 |
| Abdominal painGastrointestinal disorders | 4/193 | 2/374 |
| Oesophageal varices haemorrhageGastrointestinal disorders | 1/193 | 6/374 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 3/193 | 6/374 |
| PyrexiaGeneral disorders | 1/193 | 6/374 |
| Back painMusculoskeletal and connective tissue disorders | 2/193 | 6/374 |
| Event | Placebo | Regorafenib (Stivarga, BAY73-4506) |
|---|---|---|
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 15/193 | 194/374 |
| DiarrhoeaGastrointestinal disorders | 31/193 | 163/374 |
| Decreased appetiteMetabolism and nutrition disorders | 29/193 | 122/374 |
| HypertensionVascular disorders | 14/193 | 119/374 |
| FatigueGeneral disorders | 50/193 | 110/374 |
| Aspartate aminotransferase increasedInvestigations | 40/193 | 99/374 |
| Blood bilirubin increasedInvestigations | 30/193 | 94/374 |
| Abdominal painGastrointestinal disorders | 29/193 | 85/374 |
| PyrexiaGeneral disorders | 13/193 | 79/374 |
| NauseaGastrointestinal disorders | 26/193 | 72/374 |
| Age, Continuous(years) | Placebo | Regorafenib 160 mg (BAY73-4506) | Total |
|---|---|---|---|
| Mean | 61.1 ± 11.6 | 61.8 ± 12.4 | 61.6 ± 12.1 |
| Sex: Female, Male(Participants) | Placebo | Regorafenib 160 mg (BAY73-4506) | Total |
|---|---|---|---|
| Female | 23 | 46 | 69 |
| Male | 171 | 333 | 504 |
| Eastern cooperative oncology group (ECOG) Performance Status (PS) (data collection system-RAVE)(Participants) | Placebo | Regorafenib 160 mg (BAY73-4506) | Total |
|---|---|---|---|
| ECOG PS 0 | 130 | 247 | 377 |
| ECOG PS 1 | 64 | 132 | 196 |
| ECOG PS: Interactive voice response system (IVRS)(Participants) | Placebo | Regorafenib 160 mg (BAY73-4506) | Total |
|---|---|---|---|
| ECOG PS 0 | 129 | 251 | 380 |
| ECOG PS 1 | 65 | 128 | 193 |
| Alpha-fetoprotein (AFP) (RAVE)(Participants) | Placebo | Regorafenib 160 mg (BAY73-4506) | Total |
|---|---|---|---|
| less than (<) 400 nanogram per milliliter (ng/mL) | 107 | 217 | 324 |
| greater than or equal to (>=) 400 ng/mL | 87 | 162 | 249 |
| Alpha-fetoprotein (AFP) (IVRS)(Participants) | Placebo | Regorafenib 160 mg (BAY73-4506) | Total |
|---|---|---|---|
| < 400 ng/mL | 105 | 212 | 317 |
| >= 400 ng/mL | 89 | 167 | 256 |
| Macrovascular invasion (RAVE)(Participants) | Placebo | Regorafenib 160 mg (BAY73-4506) | Total |
|---|---|---|---|
| Absence | 140 | 269 | 409 |
| Presence | 54 | 110 | 164 |
| Macrovascular invasion (IVRS)(Participants) | Placebo | Regorafenib 160 mg (BAY73-4506) | Total |
|---|---|---|---|
| Absence | 135 | 262 | 397 |
| Presence | 59 | 117 | 176 |
3 further baseline measures are reported on the registry.
Showing the first 100 of 147 sites across 21 countries. Choose a country and city above to see the rest.
Plan to share: Undecided — Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.
Ran from May 2013 to primary completion in Feb 2016, 33 months.
Results were first posted in Jun 2017, 1 year 3 months after primary completion.
Of 53 industry-sponsored phase 3 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 63. This study's 33 months is below that.
Counting every sponsor, half of 139 studies reached it within 56 months; a quarter within 43 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Regorafenib